N-acetylgalactosamino dendron-clearing agent for dota-pretargeted radioimmunotherapy

1. A compound that is

or a pharmaceutically acceptable salt and/or solvate thereof, wherein

X 1 , X 2 , X 3 , X 4 , X 5 , X 6 , X 7 , X 8 , X 9 , X 10 , X 11 , X 12 , X 13 , X 14 , X 15 , X 16 , X 17 , X 18 , X 19 , and X 20 are each independently H or a lone pair of electrons providing an oxygen anion;

Y 1 , Y 2 , Y 3 , Y 4 and Y 5 are each independently O or S;

x is 1, 2, or 3; and

y is 1, 2, 3, or 4.

2. The compound of claim 1 , having a formula that is

or a pharmaceutically acceptable salt and/or solvate thereof, wherein

M 1 M 2 , M 3 , M 4 and M 5 are each independently Lu 3+ , Sc 3+ , Ga 3+ , Y 3+ , In 3+ , La 3+ , Ce 3+ , Eu 3+ , Tb 3+ , or Gd 3+ ;

X 1 , X 2 , X 3 , X 4 , X 5 , X 6 , X 7 , X 8 , X 9 , X 10 , X 11 , X 12 , X 13 , X 14 , X 15 , X 16 , X 17 , X 18 , X 19 , and X 20 are each independently H or a lone pair of electrons providing an oxygen anion;

Y 1 , Y 2 , Y 3 , Y 4 and Y 5 are each independently O or S;

x is 1, 2, or 3; and

y is 1, 2, 3, or 4.

3. The compound of claim 2 , wherein M 1 , M 2 , M 3 , M 4 , and M 5 are each independently not a radionuclide, or wherein Y 1 , Y 2 , Y 3 , Y 4 , and Y 5 are each independently S.

4. The compound of claim 1 , wherein x is 1 or 2 or wherein y is 2 or 3.

5. A composition comprising the compound of claim 1 and a pharmaceutically acceptable carrier.

6. A method for increasing tumor sensitivity to radiation therapy in a subject diagnosed with cancer, the method comprising

(a) administering an effective amount of an anti-DOTA bispecific antibody to the subject, wherein the anti-DOTA bispecific antibody is configured to localize to a tumor expressing a tumor antigen target;

(b) administering an effective amount of the compound of claim 1 to the subject; and

(c) administering an effective amount of a radiolabeled DOTA hapten to the subject, wherein the DOTA hapten is configured to form a complex with the anti-DOTA bispecific antibody.

7. A method for treating cancer in a subject in need thereof, the method comprising

(a) administering an effective amount of an anti-DOTA bispecific antibody to the subject, wherein the anti-DOTA bispecific antibody is configured to localize to a tumor expressing a tumor antigen target;

(b) administering an effective amount of the compound of claim 1 to the subject; and

(c) administering an effective amount of a radiolabeled DOTA hapten to the subject, wherein the DOTA hapten is configured to form a complex with the anti-DOTA bispecific antibody.

8. The method of claim 7 , further comprising sequentially, separately, or simultaneously administering to the subject at least one chemotherapeutic agent selected from the group consisting of nitrogen mustards, ethylenimine derivatives, alkyl sulfonates, nitrosoureas, gemcitabine, triazenes, folic acid analogs, anthracyclines, taxanes, COX-2 inhibitors, pyrimidine analogs, purine analogs, antibiotics, enzyme inhibitors, epipodophyllotoxins, platinum coordination complexes, vinca alkaloids, substituted ureas, methyl hydrazine derivatives, adrenocortical suppressants, hormone antagonists, endostatin, taxols, camptothecins, SN-38, doxorubicin, doxorubicin analogs, antimetabolites, alkylating agents, antimitotics, anti-angiogenic agents, tyrosine kinase inhibitors, mTOR inhibitors, heat shock protein (HSP90) inhibitors, proteosome inhibitors, HDAC inhibitors, pro-apoptotic agents, methotrexate and CPT-11.

9. The method of claim 7 , wherein the tumor antigen target is selected from the group consisting of GPA33, HER2/neu, GD2, MAGE-1, MAGE-3, BAGE, GAGE-1, GAGE-2, MUM-1, CDK4, N-acetylglucosaminyltransferase, p15, gp75, beta-catenin, ErbB2, cancer antigen 125 (CA-125), carcinoembryonic antigen (CEA), RAGE, MART (melanoma antigen), MUC-1, MUC-2, MUC-3, MUC-4, MUC-5ac, MUC-16, MUC-17, tyrosinase, Pmel 17 (gp100), GnT-V intron V sequence (N-acetylglucoaminyltransferase V intron V sequence), Prostate cancer psm, PRAME (melanoma antigen), β-catenin, EBNA (Epstein-Barr Virus nuclear antigen) 1-6, p53, lung resistance protein (LRP) Bcl-2, prostate specific antigen (PSA), Ki-67, CEACAM6, colon-specific antigen-p (CSAp), HLA-DR, CD40, CD74, CD138, EGFR, EGP-1, EGP-2, VEGF, P1GF, insulin-like growth factor (ILGF), tenascin, platelet-derived growth factor, IL-6, CD20, CD19, PSMA, CD33, CD123, MET, DLL4, Ang-2, HER3, IGF-1R, CD30, TAG-72, SPEAP, CD45, L1-CAM, Lewis Y (Le y ) antigen, E-cadherin, V-cadherin, and EpCAM.

10. The method of claim 7 , wherein the anti-DOTA bispecific antibody, the radiolabeled DOTA hapten, or the compound is administered intravenously, intramuscularly, intraarterially, intrathecally, intracapsularly, intraorbitally, intradermally, intraperitoneally, transtracheally, subcutaneously, intracerebroventricularly, orally or intranasally.

11. The method of claim 7 , wherein the cancer is selected from the group consisting of breast cancer, colorectal cancer, cervical cancer, ovarian cancer, liver cancer, bladder cancer, hepatoma, hepatocellular carcinoma, brain cancer, lung cancer, gastric or stomach cancer, pancreatic cancer, thyroid cancer, kidney or renal cancer, prostate cancer, melanoma, sarcomas, carcinomas, Wilms tumor, endometrial cancer, glioblastoma, squamous cell cancer, astrocytomas, salivary gland carcinoma, vulvar cancer, penile carcinoma, and head-and-neck cancer, optionally wherein the brain cancer is a pituitary adenoma, a meningioma, a neuroblastoma, or a craniopharyngioma.

12. The method of claim 7 , wherein the complex emits radioactive levels that are expressed as percentage injected dose per gram tissue (% ID/g).

13. The method of claim 7 , wherein the subject exhibits a tumor to normal tissue uptake ratio of about 2:1, 3:1, 4:1, 5:1, 6:1, 7:1, 8:1, 9:1, 10:1, 15:1, 20:1, 25:1, 30:1, 35:1, 40:1, 45:1, 50:1, 55:1, 60:1, 65:1, 70:1, 75:1, 80:1, 85:1, 90:1, 95:1 or 100:1.

14. The method of claim 7 , wherein the radiolabeled DOTA hapten is labelled with a radionuclide selected from the group consisting of 213 Bi, 211 At, 225 Ac, 152 Dy, 212 Bi, 223 Ra, 219 Rn 215 Po, 211 Bi, 221 Fr, 217 At, 255 Fm, 86 Y, 90 Y, 89 Sr, 165 Dy, 186 Re, 188 Re, 177 Lu, 67 Cu, 111 In, 67 Ga, 51 Cr 58 CO, 99m TC, 103m Rh, 195m Pt, 119 Sb, 161 Ho 189m Os 192 Ir, 201 TI, 203 Pb, 68 Ga, 227 Th, and 64 Cu.

15. The method of claim 14 , wherein the radiolabeled DOTA hapten comprises one or more of Proteus -DOTA, S-2-(R-aminobenzyl)-1,4,7,10-tetraazacyclododecane tetra-acetic acid (DOTA-Bn), DOTA-Bn-biotin, BAD (((S)-2-(4-(2-bromo)-acetamido)-benzyl)-DOTA), NBD ((S)-2-(4-nitrobenzyl)-DOTA), DOTA-RGD, DOTA-PEG-E(c(RGDyK)) 2 , DOTA-8-AOC-BBN, p-NO2-Bn-DOTA, DOTA-PESIN, DOTA-biotin-sarcosine (DOTA-biotin), 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid mono (N-hydroxysuccinimide ester) (DOTA-NHS), or DOTATyrLysDOTA.

16. A kit comprising a compound of claim 1 , and instructions for use.

17. The kit of claim 16 further comprising at least one anti-DOTA BsAb.

18. The kit of claim 17 , wherein the at least one anti-DOTA BsAb binds to a tumor antigen target selected from the group consisting of GPA33, HER2/neu, GD2, MAGE-1, MAGE-3, BAGE, GAGE-1, GAGE-2, MUM-1, CDK4, N-acetylglucosaminyltransferase, p15, gp75, beta-catenin, ErbB2, cancer antigen 125 (CA-125), carcinoembryonic antigen (CEA), RAGE, MART (melanoma antigen), MUC-1, MUC-2, MUC-3, MUC-4, MUC-5ac, MUC-16, MUC-17, tyrosinase, Pmel 17 (gp100), GnT-V intron V sequence (N-acetylglucoaminyltransferase V intron V sequence), Prostate cancer psm, PRAME (melanoma antigen), β-catenin, EBNA (Epstein-Barr Virus nuclear antigen) 1-6, p53, lung resistance protein (LRP) Bcl-2, prostate specific antigen (PSA), Ki-67, CEACAM6, colon-specific antigen-p (CSAp), HLA-DR, CD40, CD74, CD138, EGFR, EGP-1, EGP-2, VEGF, P1GF, insulin-like growth factor (ILGF), tenascin, platelet-derived growth factor, IL-6, CD20, CD19, PSMA, CD33, CD123, MET, DLL4, Ang-2, HER3, IGF-1R, CD30, TAG-72, SPEAP, CD45, L1-CAM, Lewis Y (Leg) antigen, E-cadherin, V-cadherin, and EpCAM.

19. The kit of claim 16 further comprising a DOTA hapten that is optionally labeled with one or more radionuclides.

20. The kit of claim 19 , wherein the one or more radionuclides are selected from the group consisting of 213 Bi, 211 At, 225 Ac, 152 Dy, 212 Bi, 223 Ra, 219 Rn, 215 Po, 211 Bi, 221 Fr, 217 At, 255 Fm, 86 Y, 90 Y, 89 Sr, 165 Dy, 186 Re, 188 Re, 177 Lu, 67 Cu, 111 In, 67 Ga, 51 Cr 58 CO, 99m TC, 103m Rh, 195m Pt, 119 Sb, 161 Ho, 189m Os, 192 Ir, 201 Tl, 203 Pb, 68 Ga, 227 Th, and 64 Cu.